Lyme Treatment for Kids: Why Children Are Missing From Clinical Research
When it comes to Lyme treatment for kids, families face a major gap: most clinical research guiding doctors comes from adult studies. Children aren’t just “small adults.” Their developing brains, immune systems, and growing bodies respond differently to both infection and treatment. Yet, the clinical trials that shape Lyme guidelines rarely include children.
Having served as an author on the International Lyme and Associated Diseases Society (ILADS) guidelines, I’ve long emphasized the need to adapt care for kids, since the evidence is so limited.
Why Pediatric Lyme Disease Needs Its Own Evidence for Treatment
Children with Lyme disease often present differently than adults. While adults may describe fatigue, joint pain, or brain fog, kids may struggle with:
-
Learning difficulties and declining school performance
-
Behavioral changes mistaken for ADHD or mood disorders
-
Sleep disturbance, irritability, or regression in daily function
-
Neurological symptoms that increase fall or injury risk
Despite these unique challenges, the NIH-sponsored Lyme trials have focused almost exclusively on adults.
Who Gets Studied in Lyme Disease Research—and Who Doesn’t
Looking at NIH-funded Lyme studies highlights the problem:
-
Klempner trial (2001): Enrolled patients ages 18–65.
-
Fallon trial (2008): Adults ages 18–70 with neurological Lyme.
-
PLEASE trial (2016): Adults ages 18–67 in Europe.
-
STOP-LD trial (2003): Adults only, ages 18–65.
Not one of these pivotal studies included children. Families looking for guidance on Lyme treatment for kids are left to rely on extrapolation from adult data—an imperfect and potentially inadequate approach.
Lyme Treatment Guidelines and the Pediatric Gap
Guideline recommendations mirror these gaps. The Infectious Diseases Society of America (IDSA) does not support extended antibiotic therapy, and their documents rarely address pediatric complexity. In contrast, the International Lyme and Associated Diseases Society (ILADS) guidelines—on which I served as an author in 2004 and 2014—stress individualized care, especially when children remain ill after standard therapy.
Why This Matters
Children have decades of life ahead of them. If Lyme disease in children is not treated adequately, the impact on education, development, and long-term health can be profound. A relapse in a 10-year-old doesn’t just mean missing school—it can alter their entire life trajectory.
Families need more than generalized statements. They need data-driven answers to questions like:
-
How long should Lyme treatment for kids last?
-
Do co-infections like Babesia or Bartonella change the approach?
-
What’s the safest way to balance antibiotics with growth and development?
Clinical Takeaways
Until research expands, clinicians and families must:
-
Recognize that children are underrepresented in Lyme research.
-
Individualize care, balancing infection control with safety.
-
Monitor not only physical symptoms, but school, mood, and cognitive changes.
-
Include families in decision-making, since parents are the ones navigating day-to-day impacts.
The Bottom Line
The biggest risk isn’t overtreating—it’s undertreating. Without trials that include children, families are left with uncertainty. That’s why Lyme treatment for kids must be guided by careful judgment, ongoing monitoring, and respect for each child’s unique needs.
✅ Have you faced challenges with Lyme treatment for your child? Share your story—your experience can help other families feel less alone.
Links
-
-
- Dr. Cameron’s blog – Only a minority of children with Lyme disease recall a tick bite
- Dr. Cameron’s blog – Study shows doctors can misdiagnose Lyme disease
- Dr. Cameron’s blog – https://danielcameronmd.com/lyme-disease-treatment-one-size-fit/
- CDC – The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America
-
